CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.86B, above the global median of $1.15B
- PositionOperating margin is 36.8%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.31%Above 5Y avg (2.53%)
Annual Rate
CNY 0.52Paid annual
Payout Ratio
77.6%Moderate
Payback Period
30.3 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.54BCNY1.86B · vs all stocks (USD)
Trailing P/E
24.36xvs Medical Devices peers
Revenue (TTM)
1.91BCNY283.65M · vs all stocks (USD)
Profit Margin
27.49%vs Medical Devices peers
Beta
0.3330xvs all stocks
52-Week Change
-33.62%vs all stocks
Market Capitalization
12.54BCNY1.86B · vs all stocks (USD)
Enterprise Value
11.31BCNY1.68B · vs all stocks (USD)
Trailing P/E
24.36xvs Medical Devices peers
Forward P/E
9.57xvs Medical Devices peers
Price to Sales (TTM)
6.72xvs Medical Devices peers
Price to Book (MRQ)
3.60xvs Medical Devices peers
Enterprise to Revenue
5.92xvs Medical Devices peers
Enterprise to EBITDA
14.25xvs Medical Devices peers
Gross Margin
79.89%vs Medical Devices peers
Profit Margin
27.49%vs Medical Devices peers
Operating Margin
36.80%vs Medical Devices peers
Return on Assets (TTM)
8.09%vs Medical Devices peers
Return on Equity (TTM)
15.98%vs Medical Devices peers
Revenue (TTM)
1.91BCNY283.65M · vs all stocks (USD)
Revenue per Share (TTM)
2.45CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-19.60%vs Medical Devices peers
Gross Profit (TTM)
1.47BCNY217.78M · vs all stocks (USD)
EBITDA (TTM)
924.19MCNY137.26M · vs all stocks (USD)
Net Income (TTM)
525.07MCNY77.98M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-19.60%vs Medical Devices peers
Operating Cash Flow (TTM)
594.15MCNY88.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
149.73MCNY22.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.5200CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
3.31%vs all stocks
5-Year Average Dividend Yield
2.53%vs all stocks
Payout Ratio
77.61%vs Medical Devices peers
Minority Interest (Equity)
-391.82KCNYFY2025 · Dec 31, 2025Revenue
2.01BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
428.50MCNYFY2025 · Dec 31, 2025Gross Profit
1.58BCNYFY2025 · Dec 31, 2025Operating Income
739.52MCNY109.83M · vs all stocks (USD)
Pre-tax Income
660.13MCNYFY2025 · Dec 31, 2025Income Tax Expense
128.46MCNYFY2025 · Dec 31, 2025Net Income
531.67MCNYFY2025 · Dec 31, 2025EBIT
713.64MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
896.71MCNYFY2025 · Dec 31, 2025Research & Development
198.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
276.92MCNYFY2025 · Dec 31, 2025Other Operating Expenses
36.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
14.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
53.51MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
772.20MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
772.20MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
531.67MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.15MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
641.15MCNYFY2025 · Dec 31, 2025Free Cash Flow
471.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.47BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
531.67MCNYFY2025 · Dec 31, 2025Other Non-cash Items
67.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
10.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.57MCNYFY2025 · Dec 31, 2025Capital Expenditures
-169.73MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.77BCNYFY2025 · Dec 31, 2025Sale of Investments
4.59BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
643.15MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
100.27MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-263.43MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-643.57MCNYFY2025 · Dec 31, 2025Other Financing Charges
243.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-563.33MCNYFY2025 · Dec 31, 2025Shares Outstanding
798.61MSharesUpdated Aug 19, 2026Float Shares
374.61MSharesUpdated Aug 19, 2026% Held by Insiders
50.39%vs all stocks
% Held by Institutions
6.73%vs all stocks
Total Cash (MRQ)
2.38BCNY353.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.08CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.24BCNY183.73M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3576xvs Medical Devices peers
Current Ratio (MRQ)
2.11xvs Medical Devices peers
Book Value per Share (MRQ)
4.47CNYUpdated Aug 19, 2026Total Assets
5.41BCNY803.34M · vs all stocks (USD)
Total Current Assets
2.92BCNYFY2025 · Dec 31, 2025Total Liabilities
1.94BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.44BCNYFY2025 · Dec 31, 2025Total Current Liabilities
502.10MCNYFY2025 · Dec 31, 2025Cash
2.24BCNYFY2025 · Dec 31, 2025Cash Equivalents
275.84MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.52BCNYFY2025 · Dec 31, 2025Other Short-term Investments
61.82KCNYFY2025 · Dec 31, 2025Accounts Receivable
29.26MCNYFY2025 · Dec 31, 2025Inventory
291.75MCNYFY2025 · Dec 31, 2025Accounts Payable
112.27MCNYFY2025 · Dec 31, 2025Short-term Debt
47.99MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.51MCNYFY2025 · Dec 31, 2025Long-term Debt
1.19BCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
798.61MCNYFY2025 · Dec 31, 2025Retained Earnings
2.43BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.47BCNY515.56M · vs all stocks (USD)
Treasury Stock
500.06MCNYFY2025 · Dec 31, 202552-Week Low
14.73CNYUpdated Aug 19, 202652-Week High
24.66CNYUpdated Aug 19, 202652-Week Change
-33.62%vs all stocks
Beta
0.3330xvs all stocks
50-Day MA
16.74CNYUpdated Aug 19, 2026200-Day MA
18.73CNYUpdated Aug 19, 2026Avg 10-Day Volume
12.50MSharesUpdated Aug 19, 2026Avg 30-Day Volume
9.84MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6600CNYUpdated Aug 19, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 36.8%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.37Industry median: 0.07Industry P95: 0.37Peers compared: 59.00
Financial Health
Altman Z-Score 5.85: safe zoneNotable
Altman Z-Score: 5.85
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.86B, above the global median of $1.15BNotable
Market cap (USD): 1,862,159,030.381Global Median: 1,146,734,693.424
Levered free cash flow is $22.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 22,237,526.518Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hebei Broadcasting & TV Information Network Co. Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Shanghai MicroPort Endovascular MedTech Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Shenzhen New Industries Biomedical Engineering Co., Ltd.
5 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels